BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, January 6, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Debiopharm targets FabI for Gram-bacterial infections with fabimycin
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Debiopharm targets FabI for Gram-bacterial infections with fabimycin
Aug. 26, 2022
No Comments
In the search for novel antibacterial agents, some targets have been engaged to kill Gram-positive but not Gram-negative organisms, due to lack of accumulation of proposed agents.
BioWorld Science
Infection